[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640000":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":7,"responsibleParty":18,"collaborators":22,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":7,"eligibilityCriteria":32,"healthyVolunteers":28,"sex":33,"minAge":34,"maxAge":35,"enrollmentInfo":36,"targetDuration":7,"studyType":39,"phases":7,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":50,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":7},{"fullName":5,"class":6},"Northwestern University","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Not applicable - observational study","This is an observational implementation study. The research team does not assign or deliver any clinical interventions. T1D screening orders and blood draws occur as part of routine care at clinician discretion, and the study observes EHR outcomes and collects surveys\u002Finterviews.\n\nParticipating clinics receive implementation supports (education, facilitation, workflow integration, and consultation) to enable routine screening adoption. These are clinic wide quality improvement activities and are not research 'interventions' assigned to participants, and clinical decisions remain at clinician discretion.",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Rinad S Beidas, PhD","CONTACT","312-503-0546","Rinad.beidas@northwestern.edu",{"type":19,"investigatorFullName":20,"investigatorTitle":21,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Rinad Beidas","Ralph Seal Paffenbarger Professor and Chair, Department of Medical Social Sciences",[23],{"name":24,"class":25},"Sanofi","INDUSTRY","100640000","type-1-diabetes-screening-100640000",false,"NCT07612475","Type 1 Diabetes Screening","Feasibility of Implementing Type One Diabetes Screening in Pediatric Clinics","Inclusion Criteria:\n\nChildren\n\n* All children presenting for the 2-4, 6-8, and 11-15 year well-child visit at participating clinics, or otherwise eligible for T1D screening, or otherwise receiving blood test recommendations from clinicians that happen outside of these recommended age buckets or routine visits, will be eligible to have their data extracted from the electronic health record (EHR)\n\nParents\u002FCaregivers\n\n\\- All parents\u002Fcaregivers who attended the well-child visit, who are eligible to have their child's data extracted, and who are over age 18, will be eligible to complete the post-visit survey and interview.\n\nClinicians and Clinical Staff\n\n* All pediatric physicians and non-physician primary care providers (MD, DO, APP) employed at participating clinics will be eligible to complete the post-visit interview.\n* All clinic staff at participating clinics, including members of the care team (e.g., medical assistants, nurses) as well as clinic leaders, administrative staff, and other staff (e.g., front-desk triage), will be eligible to complete the post-visit interview.\n\nExclusion Criteria:\n\n* Parents\u002Fcaregivers and children who have opted-out of participating in research at their clinic.","ALL","1 Year","18 Years",{"count":37,"type":38},3500,"ESTIMATED","OBSERVATIONAL","This study examines how population-based screening for type 1 diabetes (T1D) using islet autoantibodies (i.e., immune system proteins) can be incorporated into pediatric primary care during routine well-child visits. The project evaluates whether this screening approach is feasible, acceptable, and appropriate for clinicians, parents, and other key constituent groups. The study also explores how often clinicians order the test and how often families complete it when integrated into existing workflows. Insights from parents, clinicians, and organizational leaders will inform future scale-up efforts and practical strategies to improve early detection of T1D in pediatric practices across the United States.",[42],"Type 1 Diabetes (T1D)",[44,45,46,47,48,49],"Implementation Science","Pediatrics","Type 1 Diabetes","Universal Screening","Islet Autoantibodies","Population-based Screening","NOT_YET_RECRUITING","2026-05-27",{"date":53,"type":54},"2026-05-28","ACTUAL",{"date":56,"type":38},"2026-07-15",{"date":58,"type":38},"2028-11-15",{"name":5,"class":6}]